|Videos|April 20, 2017

A Larger Vision for Hospital Epidemiologists

Silvia Munoz-Price, MD, PhD, Associate Professor of Clinical Medicine at the Institute for Health and Society, Medical College of Wisconsin, and Enterprise Epidemiologist for Froedtert & the Medical College of Wisconsin, discusses some issues that she believes the subspecialty needs to address.

Silvia Munoz-Price, MD, PhD, Associate Professor of Clinical Medicine at the Institute for Health and Society, Medical College of Wisconsin, and Enterprise Epidemiologist for Froedtert & the Medical College of Wisconsin, discusses some issues that she believes the subspecialty needs to address.

Interview Transcript (slightly modified for readability)

“So I think that, during the last few decades, our subspecialty has [made] a lot of advances for the field. We have put in place bundles for the prevention of hospital-acquired infections that are widely used, not just by us, but by others within parallel fields. At this time, there are 3 issues that I think our subspecialty needs to tackle.

Number 1: certification. How do we ensure that the people that the people that are coming into the field are trained to the standards that we think are needed?

Number 2: clear articulation of our role within our hospitals, especially in regards to our relationships with quality, and with the nursing components of our infection control departments. We really should not leave that articulation of our role to individual SHEA members or individual hospital epidemiologists. Rather, it should be a SHEA decision [to define] the role of the hospital epidemiologist and antibiotic stewardship director in relation with the other parallel fields.

The last issue that I think is important is that hospital epidemiologists probably should consider expanding our domain outside the very narrow field of prevention of infections, and using and leveraging our critical and analytical minds and our highly skilled membership in order to expand to other fields in the hospital and really prove our value not just within infection control but beyond that [as well].”


Related to this article

Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
ID Week Highlights Part 1
In this first IDWeek 2026 roundup, oral olorofim matched AmBisome in invasive aspergillosis, aztreonam-avibactam held activity as MBL-producing CRE rose, pritelivir cut hospitalizations in refractory HSV, and zelicapavir shortened RSV symptoms in high-risk adults.
Pfizer 25-Valent Pneumococcal Vaccine Boosts Serotype 3 Response in Infants
Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.